These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 30964613)

  • 1. Mining Small Routine Clinical Data: A Population Pharmacokinetic Model and Optimal Sampling Times of Capecitabine and its Metabolites.
    Oyaga-Iriarte E; Insausti A; Bueno L; Sayar O; Aldaz A
    J Pharm Pharm Sci; 2019; 22(1):112-121. PubMed ID: 30964613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry.
    Deng P; Ji C; Dai X; Zhong D; Ding L; Chen X
    J Chromatogr B Analyt Technol Biomed Life Sci; 2015 May; 989():71-9. PubMed ID: 25808944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Nitrouracil stabilizes the plasma concentration values of 5-FU in colorectal cancer patients receiving capecitabine.
    Yoshida Y; Hashimoto Y; Miyazaki M; Aisu N; Yamada T; Kajitani R; Munechika T; Matsumoto Y; Nagano H; Shimaoka H; Komono A; Sakamoto R; Yoshimatsu G; Yoshimura F; Kiyomi F; Hasegawa S
    Sci Rep; 2020 Feb; 10(1):2711. PubMed ID: 32066801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients.
    Lunar N; Etienne-Grimaldi MC; Macaire P; Thomas F; Dalenc F; Ferrero JM; Pivot X; Milano G; Royer B; Schmitt A
    Cancer Chemother Pharmacol; 2021 Feb; 87(2):229-239. PubMed ID: 33386926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients.
    Di Desidero T; Orlandi P; Fioravanti A; Cremolini C; Loupakis F; Marmorino F; Antoniotti C; Masi G; Lonardi S; Bergamo F; Zagonel V; Falcone A; Bocci G
    Invest New Drugs; 2018 Aug; 36(4):709-714. PubMed ID: 29488048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of pharmacokinetic variations of capecitabine after multiple administration in rats: a physiologically based pharmacokinetic model.
    Sakai S; Kobuchi S; Ito Y; Sakaeda T
    Cancer Chemother Pharmacol; 2020 May; 85(5):869-880. PubMed ID: 32240335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients.
    Reigner B; Verweij J; Dirix L; Cassidy J; Twelves C; Allman D; Weidekamm E; Roos B; Banken L; Utoh M; Osterwalder B
    Clin Cancer Res; 1998 Apr; 4(4):941-8. PubMed ID: 9563888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients.
    Gieschke R; Burger HU; Reigner B; Blesch KS; Steimer JL
    Br J Clin Pharmacol; 2003 Mar; 55(3):252-63. PubMed ID: 12630975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer.
    Bressolle F; Joulia JM; Pinguet F; Ychou M; Astre C; Duffour J; Gomeni R
    Cancer Chemother Pharmacol; 1999; 44(4):295-302. PubMed ID: 10447576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients.
    Poole C; Gardiner J; Twelves C; Johnston P; Harper P; Cassidy J; Monkhouse J; Banken L; Weidekamm E; Reigner B
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):225-34. PubMed ID: 11935215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circadian variations in the pharmacokinetics of capecitabine and its metabolites in rats.
    Kobuchi S; Yazaki Y; Ito Y; Sakaeda T
    Eur J Pharm Sci; 2018 Jan; 112():152-158. PubMed ID: 29175408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis.
    Jacobs BAW; Deenen MJ; Joerger M; Rosing H; de Vries N; Meulendijks D; Cats A; Beijnen JH; Schellens JHM; Huitema ADR
    CPT Pharmacometrics Syst Pharmacol; 2019 Dec; 8(12):940-950. PubMed ID: 31652031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer.
    Urien S; Rezaí K; Lokiec F
    J Pharmacokinet Pharmacodyn; 2005 Dec; 32(5-6):817-33. PubMed ID: 16284918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Bayesian method for predicting 5-fluorouracil pharmacokinetic parameters following short-term infusion in patients with colorectal cancer.
    Climente-Martí M; Merino-Sanjuán M; Almenar-Cubells D; Jiménez-Torres NV
    J Pharm Sci; 2003 Jun; 92(6):1155-65. PubMed ID: 12761805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.
    Schüller J; Cassidy J; Dumont E; Roos B; Durston S; Banken L; Utoh M; Mori K; Weidekamm E; Reigner B
    Cancer Chemother Pharmacol; 2000; 45(4):291-7. PubMed ID: 10755317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetic analysis of the major metabolites of capecitabine.
    Gieschke R; Reigner B; Blesch KS; Steimer JL
    J Pharmacokinet Pharmacodyn; 2002 Feb; 29(1):25-47. PubMed ID: 12194534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma.
    Vainchtein LD; Rosing H; Schellens JH; Beijnen JH
    Biomed Chromatogr; 2010 Apr; 24(4):374-86. PubMed ID: 19650151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rapid and simple HPLC assay for quantification of capecitabine for drug monitoring purposes.
    Farkouh A; Ettlinger D; Schueller J; Georgopoulos A; Scheithauer W; Czejka M
    Anticancer Res; 2010 Dec; 30(12):5207-11. PubMed ID: 21187514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR).
    Ebi H; Sigeoka Y; Saeki T; Kawada K; Igarashi T; Usubuchi N; Ueda R; Sasaki Y; Minami H
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):205-11. PubMed ID: 15844007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cells in patients with colorectal cancer.
    Wattanatorn W; McLeod HL; Macklon F; Reid M; Kendle KE; Cassidy J
    Pharmacotherapy; 1997; 17(5):881-6. PubMed ID: 9324177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.